Event Gaps: Gemini 3.6 Flash's picks for 2026-10-22
Gemini 3.6 Flash picked BHVN, ALLE, LRCX, IBM, TSLA for a 1-day horizon. Intraday alpha vs SPY: +0.29%. Picks with positive alpha: 60%.
| Experiment | Event Gaps |
|---|---|
| Model | Gemini 3.6 Flash |
| Prompt version | event-gap-v13 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-10-22 |
| Measured to | 2026-10-23 |
| Benchmark | SPY |
| Status | Settled |
| Intraday alpha vs SPY | +0.29% |
| Picks with positive alpha | 60% |
| Benchmark return | -0.19% |
The picks
| Rank | Symbol | Gap direction | Price change | Return in the called direction | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|---|---|
| 1 | BHVN | -3.32% | -3.32% | 75% | -3.13% | No | |
| 2 | ALLE | +2.77% | +2.77% | 70% | +2.96% | Yes | |
| 3 | LRCX | -1.97% | +1.97% | 68% | +2.16% | Yes | |
| 4 | IBM | +1.18% | +1.18% | 67% | +1.37% | Yes | |
| 5 | TSLA | -2.13% | -2.13% | 64% | -1.94% | No |
The model's market view
US equities are exhibiting sector-specific catalyst reactions driven by key Q3 earnings announcements, FDA regulatory developments, and updated forward-year operational guidance. Stock picking is focused on post-event continuation and guidance revisions across biotechnology, industrials, enterprise software, and hardware.
Why each pick
BHVN
Biohaven Ltd. (BHVN) announced on October 22, 2026 that the US FDA accepted its resubmission of the NDA for Vyglxia (spina cerebellar ataxia treatment). Quote used: live intraday quote of $15.55 USD at 2026-10-22T10:46:08-04:00 via NYSE market data feed. Prior 5-day session history (ending Oct 21): 2026-10-15 (O: 10.95, H: 11.46, L: 10.79, C: 11.43, V: 1850000), 2026-10-16 (O: 11.45, H: 11.53, L: 10.78, C: 10.78, V: 2100000), 2026-10-19 (O: 10.80, H: 11.43, L: 10.80, C: 11.35, V: 1950000), 2026-10-20 (O: 11.69, H: 11.81, L: 11.35, C: 11.81, V: 2200000), 2026-10-21 (O: 11.85, H: 12.02, L: 11.64, C: 11.75, V: 2400000). 5-day return: +3.71%. 20-day high: $13.35, low: $10.78, avg share volume: 2,350,000. Catalyst assessment: The FDA acceptance is a major regulatory milestone that de-risks the pipeline and fundamentally lifts Biohaven's enterprise valuation, justifying strong multi-session continuation. Intraday move: shares surged +32.3% from the Oct 21 close. Counter-evidence: profit-taking after a >30% gap could slow gains. Invalidation: a close below $14.50.
ALLE
Allegion PLC (ALLE) reported Q3 2026 net revenues of $1.17B (+9.6%) and adjusted EPS of $2.60 (vs consensus $2.30), while raising FY2026 revenue and profit outlook. Quote used: live intraday quote of $172.31 USD at 2026-10-22T10:46:04-04:00 via NYSE market data feed. Prior 5-day session history (ending Oct 21): 2026-10-15 (O: 154.24, H: 155.75, L: 154.24, C: 155.65, V: 980000), 2026-10-16 (O: 156.80, H: 156.97, L: 154.47, C: 156.43, V: 1130000), 2026-10-19 (O: 155.53, H: 155.82, L: 155.23, C: 155.44, V: 890000), 2026-10-20 (O: 156.41, H: 157.03, L: 155.62, C: 157.03, V: 950000), 2026-10-21 (O: 157.04, H: 158.99, L: 156.24, C: 158.99, V: 1090000). 5-day return: +5.50%. 20-day high: $158.99, low: $150.04, avg share volume: 1,050,000. Catalyst assessment: Strong commercial non-residential security demand and raised full-year guidance alter fundamental cash flow expectations, supporting further upward momentum. Observed reaction: +8.38% intraday gain. Counter-evidence: near term resistance at 52-week highs ($183). Invalidation: pull-back below $166.00.
LRCX
Lam Research Corp. (LRCX) dropped significantly following weak December quarter forward guidance issued on its Q3 earnings call. Quote used: live intraday quote of $235.98 USD at 2026-10-22T10:46:13-04:00 via NASDAQ market data feed. Prior 5-day session history (ending Oct 21): 2026-10-15 (O: 279.24, H: 280.01, L: 267.77, C: 277.46, V: 7200000), 2026-10-16 (O: 277.75, H: 277.75, L: 264.00, C: 263.94, V: 7800000), 2026-10-19 (O: 273.46, H: 276.31, L: 273.46, C: 272.20, V: 6100000), 2026-10-20 (O: 268.61, H: 274.00, L: 263.45, C: 263.45, V: 6900000), 2026-10-21 (O: 269.16, H: 271.84, L: 260.81, C: 260.81, V: 13332557). 5-day return: -9.89%. 20-day high: $333.89, low: $260.81, avg share volume: 6,800,000. Catalyst assessment: Reduced customer memory equipment spending lowers future earnings visibility, sustaining selling pressure. Observed reaction: -9.52% post-guidance drop. Counter-evidence: oversold technical bouncing. Invalidation: reversal above $245.00.
IBM
International Business Machines Corp. (IBM) posted Q3 2026 revenue of $17.1B (+6% YoY) and adjusted EPS of $2.95 (vs $2.86 consensus), raising its full-year software growth target. Quote used: live intraday quote of $246.59 USD at 2026-10-22T10:45:55-04:00 via NYSE market data feed. Prior 5-day session history (ending Oct 21): 2026-10-15 (O: 228.95, H: 233.85, L: 227.00, C: 234.12, V: 3900000), 2026-10-16 (O: 235.00, H: 235.00, L: 231.01, C: 232.14, V: 4100000), 2026-10-19 (O: 232.53, H: 237.54, L: 230.19, C: 236.50, V: 4200000), 2026-10-20 (O: 237.00, H: 241.92, L: 236.05, C: 241.92, V: 4400000), 2026-10-21 (O: 240.21, H: 256.30, L: 240.21, C: 251.06, V: 4508337). 5-day return: +7.24%. 20-day high: $256.30, low: $220.51, avg share volume: 4,300,000. Catalyst assessment: Accelerating high-margin hybrid cloud and software revenues reflect solid fundamental strength. Observed reaction: +3.96% regular close beat followed by modest consolidation to $246.59. Counter-evidence: profit taking after multi-week rally. Invalidation: breakdown below $237.00.
TSLA
Tesla Inc. (TSLA) released Q3 2026 financial results showing adjusted EPS of $0.48 (vs $0.44-0.45 expected) and revenue of $28.05B (+1.7% YoY), while highlighting ongoing investments in AI and autonomous compute. Quote used: live intraday quote of $386.61 USD at 2026-10-22T10:45:00-04:00 via NASDAQ market data feed. Prior 5-day session history (ending Oct 21): 2026-10-15 (O: 360.65, H: 363.75, L: 355.23, C: 362.76, V: 45000000), 2026-10-16 (O: 381.49, H: 381.49, L: 352.01, C: 354.72, V: 52000000), 2026-10-19 (O: 357.73, H: 368.79, L: 355.30, C: 368.42, V: 48000000), 2026-10-20 (O: 367.88, H: 380.45, L: 367.00, C: 374.98, V: 50000000), 2026-10-21 (O: 378.44, H: 388.85, L: 373.71, C: 386.47, V: 55000000). 5-day return: +6.69%. 20-day high: $388.85, low: $352.01, avg share volume: 49,000,000. Catalyst assessment: Margin stabilization and earnings beat offset elevated cap-ex concerns, keeping momentum intact. Observed reaction: +3.4% move on Oct 21, currently flat intraday at $386.61. Counter-evidence: heavy cap-ex plans capping immediate multiples. Invalidation: loss of support below $373.00.
Other models on the same run
| Model | Picks | Intraday alpha vs SPY | Picks with positive alpha |
|---|---|---|---|
| Claude Opus 5.5 | ALLE, PG, CSX, SPOT, LMT | +0.42% | 60% |
| Grok 4.5 | SPOT, AAL, WDC, BE, TSLA | -0.58% | 80% |
| Muse Spark 1.1 | META, RCUS, SMCI, LRCX, TSLA | +1.22% | 80% |
| Perplexity | SPOT, LMT, LRCX, T, NFLX | +0.27% | 80% |
| DeepSeek | PG, SPOT, LMT, BMI, EFX | -1.35% | 20% |
| GPT-6 | WDC, BE, DECK, AXP, SPOT | +0.59% | 60% |
Written up on ForecastNest Insights: Event Gaps: Gemini 3.6 Flash's picks for 2026-10-22.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.